Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» CT-P13
CT-P13
Celltrion showcases positive one-year results for subcutaneous formulation of infliximab in patients with active Crohn’s disease and ulcerative colitis
Pharmaceutical Business Review
Mon, 02/17/20 - 10:20 am
Celltrion
clinical trials
CT-P13
Crohn's Disease
ulcerative colitis
Can Pharma Learn to Stop Worrying and Love Biosimilars?
Forbes
Thu, 02/11/16 - 08:28 am
biosimilars
Novartis
Celltrion
Pfizer
Zarxio
CT-P13